Food Does Not Influence the Pharmacokinetics of a New Extended Release Formulation of Tolterodine for Once Daily Treatment of Patients with Overactive Bladder

[1] Jackson S.(1997)The patient with overactive bladder: symptoms and quality of life issues Urology 50 18-22

[2] Wein A.J.(1999)The overactive bladder: an overview for primary care health providers Int J Fertil 44 56-66

[3] Rovner E.S.(1999)Tolterodine, a new antimuscarinic drug for treatment of bladder overactivity Pharmacotherapy 19 267-80

[4] Guay D.R.P.(1997)Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis Urology 50 90-6

[5] Appell R.A.(1998)Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder Br J Urol 81 801-10

[6] Abrams P.(1999)Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder Int Urogynecol J Pelvic Floor Dysfunct 10 283-9

[7] Freeman R.(2000)The mechanism of action of tolterodine Rev Contemp Pharmacother 11 13-27

[8] Anderström C.(1997)Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity Int J Clin Pharmacol Ther 35 287-95

[9] Drutz H.(1998)Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamics of tolterodine Clin Pharmacol Ther 63 529-39

[10] Appell R.A.(1998)Tolterodine, a new muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes Drug Metab Dispos 26 289-93

[1] Jackson S.(1997)The patient with overactive bladder: symptoms and quality of life issues Urology 50 18-22

[2] Wein A.J.(1999)The overactive bladder: an overview for primary care health providers Int J Fertil 44 56-66

[3] Rovner E.S.(1999)Tolterodine, a new antimuscarinic drug for treatment of bladder overactivity Pharmacotherapy 19 267-80

[4] Guay D.R.P.(1997)Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis Urology 50 90-6

[5] Appell R.A.(1998)Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder Br J Urol 81 801-10

[6] Abrams P.(1999)Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder Int Urogynecol J Pelvic Floor Dysfunct 10 283-9

[7] Freeman R.(2000)The mechanism of action of tolterodine Rev Contemp Pharmacother 11 13-27

[8] Anderström C.(1997)Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity Int J Clin Pharmacol Ther 35 287-95

[9] Drutz H.(1998)Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamics of tolterodine Clin Pharmacol Ther 63 529-39

[10] Appell R.A.(1998)Tolterodine, a new muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes Drug Metab Dispos 26 289-93